{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:10Z","timestamp":1792812670666,"version":"4.5.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:p>Adeno-associated viruses (AAV) are well-suited to serve as gene transfer vectors. Onasemnogene abeparvovec uses AAV9 as virus vector. Previous exposure to wild-type AAVs or placental transfer of maternal AAV antibodies, however, can trigger an immune response to the vector virus which may limit the therapeutic effectiveness of gene transfer and impact safety. We present the case of a female patient with spinal muscular atrophy (SMA) and three survival motor neuron 2 ( SMN2) gene copies. The infant had elevated titers of AAV9 antibodies at diagnosis at 9 days of age. Being presymptomatic at diagnosis, it was decided to retest the patient\u2019s AAV9 antibody titer at two-weekly intervals. Six weeks after initial diagnosis, a titer of 1:12.5 allowed treatment with onasemnogene abeparvovec. The presented case demonstrates that, provided the number of SMN2 gene copies and the absence of symptoms allow, onasemnogene abeparvovec therapy is feasible in patients with initially exclusionary AAV9 antibody titers of &gt;1:50.<\/jats:p>","DOI":"10.3233\/jnd-221659","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T10:52:00Z","timestamp":1706871120000},"page":"493-498","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Repeated AAV9 Titer Determination in a Presymptomatic SMA Patient with Three\n                    <i>SMN2<\/i>\n                    Gene Copies \u2013 A Case Report"],"prefix":"10.1177","volume":"11","author":[{"given":"Astrid","family":"Eisenk\u00f6lbl","sequence":"first","affiliation":[{"name":"Kepler University Hospital, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"P\u00fchringer","sequence":"additional","affiliation":[{"name":"Kepler University Hospital, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.02.011"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.11.007"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00251-9"},{"key":"ref008","unstructured":"TijsmaAS, van Gent BA, MonteiroMVA, et al. Validation of an anti-AAV9 human IgG screening ELISA. Molecular Therapy; 2020: Cell Press 50 Hampshire St, Floor 5, Cambridge, MA 02139 USA."},{"key":"ref009","unstructured":"European Medicines Agency. Zolgensma: EPAR \u2013Product Information 2022 [last accessed 29 July 2022]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/zolgensma-epar-product-information_en.pdf."},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00585-7"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.014"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00446"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.004"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.020"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/49.5.302"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2003.69.123"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.3.487"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00273-7"},{"issue":"12","key":"ref019","first-page":"Cr541","volume":"9","author":"Szenborn L","year":"2003","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research."},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.06.076"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2015.06.002"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.3233\/jnd-190468"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.11.009"},{"key":"ref026","unstructured":"European Medicines Agency. Spinraza: EPAR \u2013Product Information 2022 [last accessed 14 June 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/spinraza-epar-product-information_en.pdf."},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00446"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00336-0"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-221659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-221659","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-221659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:36Z","timestamp":1777506756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-221659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,5]]}},"alternative-id":["10.3233\/JND-221659"],"URL":"https:\/\/doi.org\/10.3233\/jnd-221659","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}